Overview


According to FutureWise analysis, the market for Anal Cancer is expected to grow at a CAGR of 6.40% over the forecast period of 2023-2031.

Anal cancer is a relatively uncommon type of cancer that starts in the cells of the anus, which is the opening at the end of the digestive tract. It is a subtype of gastrointestinal cancer and falls under the category of colorectal cancers. The anus plays a vital role in eliminating waste from the body. Like other cancers, anal cancer occurs when there is uncontrolled growth and multiplication of abnormal cells in the anal region. These cells can form tumors that have the potential to spread to nearby tissues and, in advanced cases, even metastasize to other parts of the body. The majority of anal cancers are believed to develop from the cells lining the anal canal, which is the short tube that connects the rectum to the anus. Anal canal cancers are distinct from cancers that originate in the skin around the anus, known as anal margin cancers. 

Contracting human papillomavirus (HPV) increases the chances of developing anal cancer. Other factors that might increase the risk include a history of receptive anal intercourse, a weakened immune system, and certain conditions that affect the immune system, such as HIV/AIDS. Anal cancer can be identified by certain symptoms such as bleeding from the anus, discomfort or pain in the anal region, changes in bowel movements, itching or irritation around the anus, and the presence of a lump or mass near the anus. Treatment for anal cancer often involves a combination of therapies, including surgery to remove the tumor, radiation therapy, and chemotherapy. The specific treatment approach depends on factors such as the size and stage of the cancer, as well as the patient's overall health.

FutureWise Market Research has published a report that provides an insightful analysis of Anal Cancer Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Anal Cancer Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi
  • Johnson Johnson Services, Inc.
  • Hospira, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The growth and demand for the anal cancer market are poised to be driven by several key factors. The notable increase in cases of multiple sexual partners and smoking stands as significant contributors to this growth trajectory. Moreover, the rapid surge in anal cancer prevalence coupled with the escalating incidence of sexually transmitted diseases are expected to propel the global anal cancer market's expansion during the forecast period spanning from 2023 to 2031. Advancements in technology and the growing elderly population are poised to play pivotal roles in boosting market growth. Similarly, the implementation of anal cancer screening programs, the robust presence of major market players, and the rise in disposable income are anticipated to be pivotal drivers fostering the flourishing of the anal cancer market.

By Cancer Type

  • Carcinoma in Situ
  • Squamous Cell Carcinoma
  • Adenocarcinoma
  • Basal Cell Carcinoma
  • Melanoma
  • Others

By Treatment Type

  • Chemotherapy
  • Surgery
  • Radiation Therapy
  • Immunotherapy

By End User

  • Hospitals and Clinics
  • Research and Academic Institutes
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. The North America region has emerged as a frontrunner in the anal cancer market, primarily due to the growing prevalence of anal cancer and substantial healthcare expenditure. The incidence of anal cancer has been on the rise, prompting increased medical attention and resources. With a well-developed healthcare infrastructure, particularly in the United States and Canada, the region offers advanced medical facilities and professionals equipped to efficiently diagnose and treat anal cancer cases. The region's higher healthcare spending has enabled comprehensive services, cutting-edge technologies, and access to innovative treatments. This commitment to healthcare is bolstered by awareness campaigns and screening programs, leading to early detection and improved patient outcomes.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Anal Cancer Market By Cancer Type, By Treatment Type, By End User and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Anal Cancer Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anal Cancer Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Anal Cancer Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Anal Cancer Market, By Cancer Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Carcinoma in Situ
        2. Squamous Cell Carcinoma
        3. Adenocarcinoma
        4. Basal Cell Carcinoma
        5. Melanoma
        6. Others

  • 8.   Global Anal Cancer Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Chemotherapy
        2. Surgery
        3. Radiation Therapy
        4. Immunotherapy

  • 9.   Global Anal Cancer Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals and Clinics
        2. Research and Academic Institutes
        3. Others

  • 10.   North America Anal Cancer Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Anal Cancer Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Anal Cancer Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         11.2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Anal Cancer Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Anal Cancer Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Amgen Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bristol-Myers Squibb Company
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Celgene Corporation
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Eli Lilly and Company
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. F. Hoffmann-La Roche Ltd r
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merck Co., Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Novartis AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Pfizer Inc..
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. GlaxoSmithKline plc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Sanofi
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. Johnson and Johnson Services, Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12. Hospira, Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients